RedHill Biopharma Ltd. (RDHL) stock
RDHLNasdaqPharmaceutical Preparations
$0.35+0.00 (0.00%)
Close on Nov 18, 2026Market cap $1.78MP/E –Yield –
RedHill Biopharma revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
For fiscal 2025 it was $286.00K, down 96.4% from the year before. Over ten years it grew 57.7% a year on average. The highest annual figure on record is $85.76M in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $286.00K | -96.4% |
| FY2024 | Dec 31, 2024 | $8.04M | +23.2% |
| FY2023 | Dec 31, 2023 | $6.53M | -89.4% |
| FY2022 | Dec 31, 2022 | $61.80M | -27.9% |
| FY2021 | Dec 31, 2021 | $85.76M | +33.2% |
| FY2020 | Dec 31, 2020 | $64.36M | +923.0% |
| FY2019 | Dec 31, 2019 | $6.29M | -24.7% |
| FY2018 | Dec 31, 2018 | $8.36M | +108.6% |
| FY2017 | Dec 31, 2017 | $4.01M | +3867.3% |
| FY2016 | Dec 31, 2016 | $101.00K | +3266.7% |
| FY2015 | Dec 31, 2015 | $3.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2022 | Jun 30, 2022 | $18.35M | +680.7% |
| Q2 FY2021 | Jun 30, 2021 | $21.50M | +4351.8% |
| Q2 FY2020 | Jun 30, 2020 | $20.90M | – |
| Q2 FY2019 | Jun 30, 2019 | $1.56M | – |
| Q2 FY2018 | Jun 30, 2018 | $2.35M | – |
| Q2 FY2017 | Jun 30, 2017 | $483.00K | – |
See a number that looks wrong?